Supplements That May Affect Deep Sleep and REM: What the Evidence Says

Overview Sleep isn’t a single uniform state. It flows through 90–110 minute cycles of NREM (N1, N2, and deep N3) and REM sleep. N3—or slow‑wave sleep—is linked to physical restoration, glymphatic clearance, and memory consolidation, while REM supports emotional processing and learning. Understanding how supplements may influence these stages can help align expectations and guide conversations with a clinician.

This focused review looks at what research suggests about common supplements and sleep architecture—especially deep sleep (N3) and REM—then briefly compares them with cognitive behavioral therapy for insomnia (CBT‑I), the behavioral gold standard.

A quick primer on sleep architecture

• N1: Light transition sleep; easily awakened. [Background]
• N2: Light-to-moderate sleep; sleep spindles and K‑complexes help sensory gating and memory. [Background]
• N3 (slow‑wave sleep): Deep, high‑amplitude delta waves; peaks in the first half of the night and supports recovery. [Background]
• REM: Rapid eye movement; vivid dreaming, emotional regulation, and memory integration; dominates the latter half of the night. [Background]

Key point: Healthy sleepers cycle through these stages several times nightly. Shifting the proportion of one stage can ripple through others, so “more deep sleep” is not automatically better if it fragments cycles. [Evidence: foundational sleep science]

Melatonin: Onset and circadian alignment, limited stage effects

• What it does: Melatonin helps signal biological night and can shift circadian timing. Multiple meta‑analyses report shorter sleep onset latency and small increases in total sleep time. [Evidence: strong; meta‑analyses of RCTs]
• Architecture: Polysomnography (PSG) studies generally show modest or inconsistent changes in NREM/REM percentages. The primary benefit appears to be faster onset and better alignment rather than reliably deepening N3 or altering REM. [Evidence: moderate]
• Who it may help: Delayed sleep phase, jet lag, or schedule-related misalignment. [Evidence: strong for circadian phase shifting]

Magnesium (with a focus on glycinate): Calming tone, mixed signals on deep sleep

• What it does: Magnesium participates in neuronal excitability and GABAergic tone. Systematic reviews suggest small improvements in subjective sleep quality and efficiency, particularly in older adults or those with low magnesium status. [Evidence: moderate; systematic reviews/RCTs]
• Architecture: Limited PSG data. Small trials report trends toward increased slow‑wave activity or improved sleep efficiency, but findings are inconsistent and sample sizes are small; specific evidence for the glycinate form and N3 enhancement remains preliminary. [Evidence: emerging]
• Practical note: Benefits may be more likely when anxiety, muscle tension, or deficiency contribute to poor sleep. [Evidence: emerging]

Glycine: Thermoregulation and possible slow‑wave support

• What it does: Glycine may promote peripheral vasodilation and a slight drop in core body temperature, which can ease the transition to sleep and reduce next‑day fatigue. Randomized trials report better subjective sleep quality and daytime functioning. [Evidence: moderate; RCTs]
• Architecture: Limited PSG findings suggest increased delta power in early sleep and a tendency toward faster entry into deeper NREM in some participants, though results are not uniform. [Evidence: emerging]
• Takeaway: Research suggests glycine may help sleep continuity and next‑day alertness, with preliminary signals for deep sleep support. [Evidence: moderate to emerging]

Apigenin (notably from chamomile): Anxiolytic potential, sparse stage data

• What it does: Apigenin is a flavonoid with GABA‑A receptor activity in preclinical models. Human studies of chamomile extracts (which contain apigenin among other constituents) report modest improvements in sleep quality and anxiety in select groups. [Evidence: moderate for chamomile overall; emerging for apigenin specifically]
• Architecture: Human PSG data isolating apigenin’s effect on N3 or REM are lacking. [Evidence: emerging]
• Eastern perspective: Chamomile is used traditionally to “settle the spirit”; modern hypotheses focus on gentle anxiolysis that may reduce presleep arousal. [Evidence: traditional + emerging]

Tart cherry juice: Small increases in total sleep time, limited architecture data

• What it does: Tart cherries contain melatonin and polyphenols with anti‑inflammatory properties. Small RCTs in older adults with insomnia report modest increases in total sleep time and sleep efficiency, along with higher urinary melatonin. [Evidence: moderate; small RCTs]
• Architecture: Stage-specific changes (N3 or REM proportions) are not well established; benefits appear more global and may reflect circadian and anti‑inflammatory effects. [Evidence: emerging]

Traditional botanicals and sleep stages

• Valerian (Valeriana officinalis): Traditionally used as a nervine sedative. Meta‑analyses show mixed results, with low-to-moderate certainty evidence for improving subjective sleep quality and possibly reducing sleep latency. Consistent PSG changes in N3/REM are not established. [Evidence: moderate for subjective quality; emerging for architecture]
• Passionflower (Passiflora incarnata): Limited RCTs suggest improved subjective sleep quality in healthy adults, and combination formulas (often with valerian and hops) may help mild insomnia. Architecture data are sparse. [Evidence: emerging]
• Jujube seed (Ziziphus jujuba, Suan Zao Ren): A core herb in East Asian formulas for insomnia, traditionally said to “nourish Heart and Liver” and calm shen (spirit). Modern hypotheses include GABAergic and serotonergic modulation. Systematic reviews of small trials suggest potential benefits for sleep quality, though study quality is variable; stage-level outcomes are rarely measured. [Evidence: traditional with emerging clinical support]

How does this compare with CBT‑I?

• Effectiveness: CBT‑I is recommended as first‑line therapy for chronic insomnia by professional societies. Meta‑analyses show meaningful reductions in sleep onset latency and wake after sleep onset, and improved sleep efficiency, with durable benefits months after treatment. [Evidence: strong]
• Architecture: CBT‑I does not target stages directly. However, by stabilizing schedules, reducing conditioned arousal, and optimizing sleep opportunity, PSG studies suggest it may normalize sleep continuity and, over time, allow healthy expression of N3 and REM without pharmacologic manipulation. [Evidence: moderate]
• Practical takeaway: Supplements may nudge onset or continuity and could influence deep sleep in select contexts, but CBT‑I addresses root behavioral and cognitive drivers and shows the most durable, broad improvements.

Putting it together: choosing a stage‑aware approach

• If sleep onset is the main issue: Melatonin may help align timing and reduce latency, particularly with circadian delay or jet lag. [Evidence: strong]
• If unrestorative sleep or night awakenings prevail: Glycine and magnesium show small-to-moderate improvements in sleep continuity in some trials; stage-specific deep sleep gains are not guaranteed. [Evidence: moderate to emerging]
• If anxiety is prominent: Chamomile/apigenin, valerian, and passionflower have traditional use and some clinical support for reducing presleep arousal; hard evidence for N3/REM shifts is limited. [Evidence: moderate to emerging]
• For comprehensive improvement: CBT‑I offers the strongest and most durable evidence and can be combined with lifestyle strategies (light exposure timing, wind‑down routines, temperature and light control) to support healthy expression of sleep stages. [Evidence: strong]

Safety and context

• Interactions: Botanicals and nutrients can interact with medications or health conditions. Melatonin can shift circadian timing; valerian and passionflower may have additive sedative effects; jujube seed is often used in formulas that warrant professional guidance. [Evidence: general pharmacology]
• Expectations: Even when a supplement shows promise, individual responses vary, and measurable changes in deep sleep or REM on wearables do not always translate to clinical benefit. PSG remains the gold standard for architecture. [Evidence: foundational]

Bottom line

• Melatonin: Helps sleep onset and circadian alignment; consistent changes to deep sleep or REM are modest at best. [Evidence: strong for onset; moderate for architecture]
• Magnesium (glycinate): May improve subjective sleep and efficiency, with preliminary signals for deep sleep support in select groups; evidence remains mixed. [Evidence: moderate overall; emerging for N3]
• Glycine: Improves subjective sleep and next‑day function; limited data suggest potential enhancement of early-night delta power. [Evidence: moderate for symptoms; emerging for architecture]
• Apigenin/chamomile: Gentle anxiolytic effects may aid sleep quality; stage-specific evidence is lacking. [Evidence: moderate for chamomile; emerging for apigenin]
• Tart cherry: May modestly extend total sleep time; architecture effects are not well defined. [Evidence: moderate]
• Traditional herbs (valerian, passionflower, jujube seed): Long history of use with some supportive trials; robust stage-level data are scarce. [Evidence: traditional to emerging]
• Compared with supplements, CBT‑I shows the strongest, most durable improvements in insomnia and may indirectly normalize sleep architecture. [Evidence: strong]

This article is informational and not a substitute for professional care. Discuss supplement use and sleep concerns with a qualified clinician, especially if you have medical conditions, take medications, or experience significant daytime impairment.